Functional Dysconnectivity of Frontal Cortex to Striatum Predicts Ketamine Infusion Response in Treatment-Resistant Depression
Year: 2020
Type: article
Study design: Clinical Trial
Abstract: BACKGROUND: Frontostriatal disconnectivity plays a crucial role in the pathophysiology of major depressive disorder. However, whether the baseline functional connectivity of the frontostriatal network could predict the treatment outcome of low-dose ketamine infusion remains unknown. METHODS: In total, 48 patients with treatment-resistant depression were randomly divided into 3 treatment groups (a single-dose 40-minute i.v. infusion) as follows: 0.5 mg/kg ketamine, 0.2 mg/kg ketamine, and saline placebo infusion. Patients were subsequently followed-up for 2 weeks. Resting-state functional magnetic resonance imaging was performed for each patient before infusion administration. In addition, the baseline frontostriatal functional connectivity of patients with treatment-resistant depression was also compared with that of healthy controls. RESULTS: Compared with the healthy controls, patients with treatment-resistant depression had a decreased functional connectivity in the frontostriatal circuits, especially between the right superior frontal cortex and executive region of the striatum and between the right paracingulate cortex and rostral-motor region of the striatum. The baseline hypoconnectivity of the bilateral superior frontal cortex to the executive region of the striatum was associated with a greater reduction of depression symptoms after a single 0.2-mg/kg ketamine infusion. CONCLUSION: Reduced connectivity of the superior frontal cortex to the striatum predicted the response to ketamine infusion among patients with treatment-resistant depression.
DOI: 10.1093/ijnp/pyaa056
Authors: Mu-Hong Chen, Wan-Chen Chang, Wei-Chen Lin, Pei-Chi Tu, Cheng-Ta Li, Ya-Mei Bai, Shih-Jen Tsai, Wen-Sheng Huang, Tung-Ping Su
Language: English
Subfield: Pharmacology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,693
Awards: G1033459439, G1347976027, G1587773336, G1685607362, G1743868987, G192736653, G2054891077, G209031205, G2291507571, Pro-Inflammatory Cytokines, Neurocognitive Function, and Neuroimaging in Adolescents with Bipolar Disorder, Unipolar Depressive Disorder, and Disruptive Mood Dysregulation Disorder: a Prospective Follow-Up Study, G270851807, G2716742842, G273981281, G3048717457, G3065783652, G3154576040, G3981284437, G4002888105, G40078815, G4194506929, G4239978428, G4263125663, G4486966945, G4529816826, G4549449143, G5072617215, G5285952827, G5343291647, G5362347854, G5375410219, G5700400475, G5752735496, G5756013894, G5833148936, G5975790557, G6102085486, G6307467193, G6331865623, G7525745040, G7716809546, A Double-Blind, Randomized-Controlled Trial Using a Low Dose of Ketamine Vs. Active Placebo in Treating Severe Depression and Suicide., G8096267062, G8117934520, G858094531, G8831620171, G8863762303, G935141799
OpenAlex ID: W3045992274
